Rockwell Medical outlines $70M-$75M 2026 net sales outlook while targeting positive net income in H2 2026

Earnings Call Insights: Rockwell Medical (RMTI) Q1 2026

MANAGEMENT VIEW

* CEO Mark Strobeck framed the quarter as continued execution on a multi-year turnaround, saying, "Fast forward to today, Rockwell is a sustainably profitable, stable company," and added, "With these additional changes, our goal is to achieve positive net income in the second half of 2026, subject to customary risks and uncertainties that could cause actual results to differ materially."
* Strobeck said demand remained strong, particularly for liquid bicarbonate concentrates, stating, "we have now become the primary supplier of liquid bicarbonate in the United States," while also noting Q1 net sales were "higher than expected" but lower year-over-year due to "our then largest customers' volumes declining."
* Strobeck highlighted operational and pricing actions intended to lift profitability starting in Q2, including, "we are activating two new automated liquid lines this quarter, which we anticipate will generate an approximate 50% increase in our output and a significant reduction in our manufacturing cost per bottle," and, "we estimate that these modifications will result in an additional $3 million of gross profit, approximately half of which we expect to realize in 2026."
* CFO Jesse Neri reported, "Net sales for the first quarter were $17.3 million," and said results "track toward our full year 2026 estimate of $70 million to $75 million," while adding, "Gross margin for the first quarter 2026 was 17%."

OUTLOOK

* Management issued 2026 annual guidance: Strobeck said, "Net sales will be between $70 million and $75 million. Gross margin will be between 18% and 22%. Our business will be profitable. We estimate adjusted EBITDA will be between $1 million and $2 million, and operating cash flow will be positive, meaning we will generate cash and eliminate our need to raise additional capital to fund our operations."
* Strobeck positioned Q2 as the first quarter reflecting recently implemented operational and pricing changes, saying, "All of these changes will be in place and be reflected in our results starting in the second quarter, positively impacting our performance in 2026."
* Compared with the prior quarter’s call, Rockwell moved from withholding net sales and gross margin guidance (while citing ongoing large-customer negotiations) to providing specific net sales and gross margin ranges for 2026.
* The analysts estimates file provided in the prompt did not include a usable EPS estimate and the revenue estimates formatting did not match the required schema for validation, so no comparison is included.

FINANCIAL RESULTS

* Neri said, "Gross profit for the first quarter 2026 was $2.9 million," and "Net loss for Q1 2026 was $1.6 million," while adjusted EBITDA was, "a negative $300,000," which he said reflected seasonal first-quarter items.
* Liquidity and cash usage were outlined as, "Cash, cash equivalents and investments available for sale at March 31, 2026, was $23.9 million compared to $25 million at year-end," and Neri attributed the decrease to seasonal items and "a $500,000 payment associated with our Evoqua acquisition," adding, "The final Evoqua payment was made in April."

Q&A

* Jeremy Pearlman, Maxim Group LLC: asked about international expansion and margin differences; CEO Mark Strobeck: said demand was strong "particularly in areas of Latin America and South America" and described selling via distributors where "our margins are typically higher in that product category," while adding, "We don't -- we don't provide the details around that."
* Pearlman, Maxim Group LLC: asked for an update on the Western U.S. expansion and when a distribution point/factory might make sense; CEO Strobeck: said Rockwell "transitioned those 30 customers into the Rockwell platform" and is "hiring drivers and establishing cross-dock out in that area" to support expansion, adding that being present in the region is generating inbound interest.
* Pearlman, Maxim Group LLC: asked whether pricing actions were only for new customers and whether there was pushback; CEO Strobeck: said pricing is evaluated continuously and applied to both new and existing customers, and stated, "at this point, we've not achieved any pushback on that."
* Pearlman, Maxim Group LLC: asked about the status of DaVita negotiations and contract duration; CEO Strobeck: said Rockwell maintains "a very good relationship with DaVita," is supplying requested facilities, and added, "DaVita did make a onetime large purchase this quarter -- in the second quarter, again, which indicates for us that they are very interested in continuing to work with us to supply them."

SENTIMENT ANALYSIS

* Analyst tone was neutral and operationally focused, with questions centered on expansion execution, pricing resilience, and DaVita visibility (e.g., Pearlman asked, "has there been any pushback" and "Is there any update" on DaVita).
* Management tone was slightly positive and confident in operational leverage and pricing, with Strobeck pointing to improving trends and stating, "we expect that trend to continue in the coming months," while avoiding disclosure on certain details (e.g., "We don't -- we don't provide the details around that").
* Versus the previous quarter, management appeared more concrete on near-term financial framing by providing explicit net sales and gross margin ranges for 2026 rather than indicating guidance would be provided later.

QUARTER-OVER-QUARTER COMPARISON

* Guidance posture shifted: in Q4 2025, Strobeck said Rockwell would provide net sales and gross margin guidance "in the near future" due to negotiations; in Q1 2026, he provided full-year ranges for net sales ($70 million to $75 million) and gross margin (18% to 22%).
* Strategic emphasis remained consistent on customer diversification and operational efficiency, with Q1 2026 adding a specific automation catalyst ("two new automated liquid lines") and a quantified gross profit impact estimate ("an additional $3 million of gross profit").
* Analyst focus narrowed in Q1 2026 to a single analyst and concentrated on three themes—international margins, Western expansion build-out, and pricing/DaVita continuity—compared with broader competitive and long-term questions in Q4 2025.

RISKS AND CONCERNS

* Customer volume risk remained explicit: Strobeck said year-over-year net sales declined because "our then largest customers' volumes declining."
* Execution risk sits in the operational transition, with management tying 2026 improvement to changes that will be "reflected in our results starting in the second quarter."
* DaVita concentration and continuity remained a recurring investor topic; Strobeck addressed it through relationship framing and recent purchasing activity, but did not provide a contract expansion commitment for periods beyond what is discussed.

FINAL TAKEAWAY

Management emphasized demand strength and a more diversified customer base while tying the 2026 plan to operational streamlining, pricing updates, and automation expected to begin showing up in Q2 results. Rockwell’s 2026 outlook centered on $70 million to $75 million in net sales, 18% to 22% gross margin, adjusted EBITDA of $1 million to $2 million, and positive operating cash flow, alongside Strobeck’s stated goal of positive net income in the second half of 2026.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/rmti/earnings/transcripts]

MORE ON ROCKWELL MEDICAL

* Rockwell Medical, Inc. (RMTI) Q1 2026 Earnings Call Transcript [https://seekingalpha.com/article/4900945-rockwell-medical-inc-rmti-q1-2026-earnings-call-transcript]
* Rockwell Medical, Inc. 2025 Q4 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4886855-rockwell-medical-inc-2025-q4-results-earnings-call-presentation]
* Rockwell Medical, Inc. (RMTI) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4886168-rockwell-medical-inc-rmti-q4-2025-earnings-call-transcript]
* Rockwell Medical Non-GAAP EPS of -$0.01, revenue of $17.34M misses by $0.61M [https://seekingalpha.com/news/4588100-rockwell-medical-non-gaap-eps-of-0_01-revenue-of-17_34m-misses-by-0_61m]
* Rockwell Medical Q1 Earnings Preview [https://seekingalpha.com/news/4587085-rockwell-medical-q1-earnings-preview]